

Shahin Akhondzadeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3485824/publications.pdf>

Version: 2024-02-01

353
papers

11,974
citations

20817

60
h-index

40979

93
g-index

357
all docs

357
docs citations

357
times ranked

11056
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of saffron as adjunctive therapy in adults with attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled clinical trial. <i>Advances in Integrative Medicine</i> , 2022, 9, 37-43.	0.9	7
2	Protection against the Omicron and Subsequent Coronavirus Variants: Medical-grade Masking, Third Dose Vaccination, Updating Vaccines, and Pursuing Universal Vaccine. <i>Avicenna Journal of Medical Biotechnology</i> , 2022, 14, 1-2.	0.3	2
3	Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial. <i>Psychopharmacology</i> , 2022, 239, 551-559.	3.1	5
4	Oxcarbazepine versus sodium valproate in treatment of acute mania. <i>International Clinical Psychopharmacology</i> , 2022, Publish Ahead of Print, .	1.7	2
5	Possible effects of Saffron (<i>Crocus sativus</i>) in the treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled trial. <i>Journal of Herbal Medicine</i> , 2022, 32, 100551.	2.0	2
6	Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran. <i>Drug and Alcohol Review</i> , 2022, 41, 895-901.	2.1	1
7	Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. <i>International Clinical Psychopharmacology</i> , 2022, 37, 92-101.	1.7	7
8	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	2.6	49
9	Efficacy of Spironolactone As an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia; A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2022, 17, 14-23.	0.7	2
10	Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. <i>International Clinical Psychopharmacology</i> , 2022, 37, 46-53.	1.7	4
11	Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 505-511.	1.8	10
12	Professor Moslem Bahadori (1927-2022), a Matchless Role Model in Modern Academic Medicine in Iran. <i>Archives of Iranian Medicine</i> , 2022, 25, 347-352.	0.6	0
13	Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial. <i>Child Psychiatry and Human Development</i> , 2021, 52, 928-938.	1.9	13
14	The effects of opium tincture and methadone on the cognitive function of patients with opioid use disorder. <i>Personality and Individual Differences</i> , 2021, 169, 110091.	2.9	1
15	The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110091.	4.8	14
16	Efficacy and safety of tipegidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 57-62.	1.8	3
17	Vitamin E and ginseng combined supplement for treatment of male erectile dysfunction: A double-blind, placebo-controlled, randomized, clinical trial. <i>Advances in Integrative Medicine</i> , 2021, 8, 44-49.	0.9	4
18	Infectious Agents and Stroke: A Systematic Review. <i>Basic and Clinical Neuroscience</i> , 2021, 12, 427-440.	0.6	6

#	ARTICLE	IF	CITATIONS
19	The Requisiteness for not Sacrificing Medical Biotechnology in the Coronavirus Era. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 53.	0.3	0
20	Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2021, 16, 52-59.	0.7	1
21	Medicinal Plants in the Treatment of Obsessive-Compulsive Disorder: A Review. <i>Current Drug Discovery Technologies</i> , 2021, 18, 8-16.	1.2	4
22	How the US Sanctions Are Affecting the Health Research System in Iran?. <i>Archives of Iranian Medicine</i> , 2021, 24, 101-106.	0.6	9
23	Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. <i>International Clinical Psychopharmacology</i> , 2021, 36, 140-146.	1.7	11
24	Prospects of Saffron and its Derivatives in Alzheimer's Disease. <i>Archives of Iranian Medicine</i> , 2021, 24, 233-252.	0.6	9
25	Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 280-304.	2.1	13
26	Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence. <i>Archives of Iranian Medicine</i> , 2021, 24, 409-418.	0.6	2
27	Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 250-255.	1.8	15
28	Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial. <i>IJC Heart and Vasculature</i> , 2021, 34, 100789.	1.1	0
29	Medical Biotechnology in the Service of Coronavirus Vaccine Discovery and Production. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 105-106.	0.3	0
30	The Necessity of Preserving the Research System in Emergency Eras. <i>Archives of Iranian Medicine</i> , 2021, 24, 583-584.	0.6	0
31	Efficacy and tolerability of <i>Lavandula angustifolia</i> in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. <i>Journal of Complementary and Integrative Medicine</i> , 2021, .	0.9	1
32	The efficacy of vitamin B6 as an adjunctive therapy to lithium in improving the symptoms of acute mania in patients with bipolar disorder, type 1; a double-blind, randomized, placebo-controlled, clinical trial. <i>Brain and Behavior</i> , 2021, 11, e2394.	2.2	6
33	Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychosomatic Research</i> , 2021, 150, 110635.	2.6	7
34	Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 799-807.	4.7	2
35	Basic Science and Clinical Studies on Non-COVID-19 Topics, of Coronavirus Victims. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 1.	0.3	0
36	Basic Science and Clinical Studies on Non-COVID-19 Topics, of Coronavirus Victims. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 1.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Expectations of Health Researchers From Academic Social Network Sites: Qualitative Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e24643.	4.3	2
38	Integrating Psychiatry and Medical Biotechnology as a Way to Achieve Scientific, Precision, and Personalized Psychiatry.. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 172-175.	0.3	0
39	Is transcranial direct current stimulation an effective modality in reducing food craving? A systematic review and meta-analysis. <i>Nutritional Neuroscience</i> , 2020, 23, 55-67.	3.1	34
40	Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 97-104.	1.5	7
41	A placebo controlled randomized clinical trial of <i>Crocus sativus</i> L. (saffron) on depression and food craving among overweight women with mild to moderate depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 134-143.	1.5	20
42	Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 324-334.	1.5	27
43	<i>Cinnamomum tamala</i> as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control. <i>Advances in Integrative Medicine</i> , 2020, 7, 141-147.	0.9	3
44	Efficacy of melatonin as an adjunct in the treatment of acute mania. <i>International Clinical Psychopharmacology</i> , 2020, 35, 81-88.	1.7	12
45	Efficacy and safety of <i>Sophora alopecuroides</i> var. <i>alopecuroides</i> seed extract for opioid detoxification: A randomized, double-blind, and placebo-controlled clinical trial. <i>Phytotherapy Research</i> , 2020, 34, 1108-1113.	5.8	7
46	Application of saffron as a neuroprotective agent. , 2020, , 445-450.		0
47	5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. <i>International Clinical Psychopharmacology</i> , 2020, 35, 254-262.	1.7	13
48	Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial?. <i>Clinical Neuropharmacology</i> , 2020, 43, 139-145.	0.7	9
49	Vitamin E and ginseng supplementation to enhance female sexual function: a randomized, double-blind, placebo-controlled, clinical trial. <i>Women and Health</i> , 2020, 60, 1164-1173.	1.0	8
50	Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 804-811.	1.5	13
51	Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial. <i>Journal of Integrative Medicine</i> , 2020, 18, 409-415.	3.1	4
52	Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. <i>Journal of Psychopharmacology</i> , 2020, 34, 506-513.	4.0	19
53	A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 236-242.	1.4	5
54	L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2020, 267, 131-136.	4.1	17

#	ARTICLE	IF	CITATIONS
55	Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 398-405.	1.8	29
56	Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. <i>Clinical Neuropharmacology</i> , 2020, 43, 39-45.	0.7	18
57	Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 775-782.	2.1	16
58	A Tool to Reduce the Problems of Iranian Health Researchers. <i>Iranian Journal of Public Health</i> , 2020, 49, 2441-2442.	0.5	2
59	Development of Evaluation System for Iranian Health Research Networks: Challenges and Lessons Learned. <i>Iranian Journal of Public Health</i> , 2020, 49, 104-113.	0.5	0
60	Repositioning Drugs for Psychiatry. <i>Avicenna Journal of Medical Biotechnology</i> , 2020, 12, 67.	0.3	0
61	Knowledge production in Iranian cardiovascular research centers: A way to reduce the burden of disease. <i>ARYA Atherosclerosis</i> , 2020, 16, 72-78.	0.4	0
62	Evaluation of Drug and Alcohol Abuse in People Aged 15 Years and Older in Iran. <i>Iranian Journal of Public Health</i> , 2020, 49, 1940-1946.	0.5	1
63	Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 137.	0.9	0
64	Efficacy and safety of titepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 690-696.	1.8	13
65	Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 170-175.	1.7	7
66	Crocus Sativus L. (saffron) versus sertraline on symptoms of depression among older people with major depressive disorders—a double-blind, randomized intervention study. <i>Psychiatry Research</i> , 2019, 282, 112613.	3.3	29
67	Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 1407-1414.	4.0	19
68	Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial. <i>International Journal of Methods in Psychiatric Research</i> , 2019, 28, e1768.	2.1	14
69	Possibility for science without borders in the Trump era. <i>Lancet, The</i> , 2019, 393, 405-406.	13.7	3
70	Saffron: The Golden Spice with Therapeutic Properties on Digestive Diseases. <i>Nutrients</i> , 2019, 11, 943.	4.1	96
71	Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1619-1628.	4.7	19
72	Therapeutic effects of saffron (<i>Crocus sativus</i>) versus fluoxetine on Irritable Bowel Syndrome: A double-blind randomized clinical trial. <i>Advances in Integrative Medicine</i> , 2019, 6, 167-173.	0.9	6

#	ARTICLE	IF	CITATIONS
73	<i>Crocus sativus</i> L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 205-212.	1.3	26
74	Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Clinical Neuropharmacology</i> , 2019, 42, 189-196.	0.7	10
75	Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 305-315.	4.0	11
76	Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 169-174.	1.8	10
77	Monoclonal Antibody a Promising Treatment for Depression. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 1-2.	0.3	21
78	Microbiota and Autism Spectrum Disorder. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 129.	0.3	1
79	Depression and Inflammation: Is There any Role for Biomarkers?. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 207.	0.3	2
80	Microbiome and Schizophrenia. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 269.	0.3	3
81	Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. <i>Journal of Affective Disorders</i> , 2018, 235, 236-241.	4.1	55
82	L-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 331-338.	1.3	16
83	Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2018, 232, 127-133.	4.1	46
84	L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. <i>Psychiatry Research</i> , 2018, 262, 94-101.	3.3	19
85	Efficacy of <i>Crocus sativus</i> (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 717-724.	1.7	48
86	Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: Placebo-controlled trial. <i>Advances in Integrative Medicine</i> , 2018, 5, 69-74.	0.9	6
87	Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2018, 103, 104-111.	3.1	30
88	Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. <i>Clinical Nutrition ESPEN</i> , 2018, 25, 37-43.	1.2	27
89	Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 82-89.	1.3	17
90	Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence. <i>International Clinical Psychopharmacology</i> , 2018, 33, 111-119.	1.7	19

#	ARTICLE	IF	CITATIONS
91	<sc>l</sc>-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 74-81.	1.3	22
92	Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. Journal of Alternative and Complementary Medicine, 2018, 24, 361-368.	2.1	25
93	Author's Reply to the Letter to the Editor by Fountoulakis. Pharmacopsychiatry, 2018, 51, 106-107.	3.3	0
94	The effects of alcoholic extract of saffron (<i>Crocus sativus</i> L.) on mild to moderate comorbid depression-anxiety, sleep quality, and life satisfaction in type 2 diabetes mellitus: A double-blind, randomized and placebo-controlled clinical trial. Complementary Therapies in Medicine, 2018, 41, 196-202.	2.7	43
95	Setting research priorities to achieve long-term health targets in Iran. Journal of Global Health, 2018, 8, 020702.	2.7	19
96	Infectious agents and different course of multiple sclerosis: a systematic review. Acta Neurologica Belgica, 2018, 118, 361-377.	1.1	18
97	Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiology and Behavior, 2018, 195, 151-157.	2.1	22
98	Citicoline (<sc>CDP</sc>-choline) addition therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: <sc>A</sc> double-blind, randomized placebo-controlled trial. Human Psychopharmacology, 2018, 33, e2662.	1.5	7
99	The effect of saffron (<i>Crocus sativus</i> L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial. Journal of Research in Medical Sciences, 2018, 23, 16.	0.9	48
100	New Hopes for Treatment of Alzheimer's Disease. Avicenna Journal of Medical Biotechnology, 2018, 10, 1.	0.3	9
101	Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry, 2018, 13, 1-9.	0.7	21
102	Opioid Use Disorder Induces Oxidative Stress and Inflammation: The Attenuating Effect of Methadone Maintenance Treatment. Iranian Journal of Psychiatry, 2018, 13, 46-54.	0.7	18
103	Monoclonal Antibody for Reducing Memory and Learning Problems in Schizophrenia. Avicenna Journal of Medical Biotechnology, 2018, 10, 125.	0.3	0
104	Saffron () versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial. Avicenna Journal of Phytomedicine, 2018, 8, 513-523.	0.2	4
105	Fluticasone propionate in clinically suspected asthma patients with negative methacholine challenge test. Clinical Respiratory Journal, 2017, 11, 433-439.	1.6	3
106	Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. Human Psychopharmacology, 2017, 32, e2583.	1.5	10
107	A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 494-500.	1.3	32
108	L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Human Psychopharmacology, 2017, 32, e2584.	1.5	25

#	ARTICLE	IF	CITATIONS
109	Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy. <i>Addiction</i> , 2017, 112, 415-429.	3.3	17
110	Simvastatin adjunct therapy for negative symptoms of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 87-94.	1.7	24
111	Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. <i>Psychiatry Research</i> , 2017, 255, 59-65.	3.3	35
112	Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Neuropharmacology</i> , 2017, 40, 1-5.	0.7	23
113	Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 440-444.	1.3	32
114	More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia. <i>Evidence-Based Mental Health</i> , 2017, 20, e3-e3.	4.5	2
115	The effect of saffron (<i>Crocus sativus</i> L.) hydro-alcoholic extract on liver and renal functions in type 2 diabetic patients: A double-blinded randomized and placebo control trial. <i>Journal of Nutrition & Intermediary Metabolism</i> , 2017, 9, 6-11.	1.7	28
116	Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. <i>Journal of Psychiatric Research</i> , 2017, 94, 70-77.	3.1	6
117	Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 44-50.	1.5	32
118	Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. <i>Pharmacopsychiatry</i> , 2017, 50, 64-68.	3.3	47
119	<i>Crocus sativus</i> L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. <i>Pharmacopsychiatry</i> , 2017, 50, 152-160.	3.3	65
120	Role of Melatonin in Body Weight: A Systematic Review and Meta-Analysis. <i>Current Pharmaceutical Design</i> , 2017, 23, 3445-3452.	1.9	24
121	Contribution of health researches in national knowledge production: A scientometrics study on 15-year research products of Iran. <i>International Journal of Preventive Medicine</i> , 2017, 8, 27.	0.4	12
122	Research in Iran: An Overview. <i>Avicenna Journal of Medical Biotechnology</i> , 2017, 9, 1.	0.3	17
123	The Reliability and Validity of the Persian Version of Three-Factor Eating Questionnaire-R18 (TFEQ-R18) in Overweight and Obese Females. <i>Iranian Journal of Psychiatry</i> , 2017, 12, 100-108.	0.7	29
124	Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2017, 12, 154-162.	0.7	13
125	Development of Health Research Structures Over the Last 25 Years: Main Achievements and Challenges. <i>Archives of Iranian Medicine</i> , 2017, 20, 659-664.	0.6	5
126	Medical Science and Research in Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, 665-672.	0.6	10

#	ARTICLE	IF	CITATIONS
127	Research Ranking of Iranian Universities of Medical Sciences Based on International Indicators: An Experience From I.R. of Iran. Archives of Iranian Medicine, 2017, 20, 673-679.	0.6	7
128	How to Assess Quality of Research in Iran, From Input to Impact? Introduction of Peer-Based Research Evaluation Model in Iran. Archives of Iranian Medicine, 2017, 20, 680-685.	0.6	4
129	Diseases and Health Outcomes Registry Systems in I.R. Iran: Successful Initiative to Improve Public Health Programs, Quality of Care, and Biomedical Research. Archives of Iranian Medicine, 2017, 20, 696-703.	0.6	7
130	Trends of Mental Health Status in Iranian Population Aged 15 and above between 1999 and 2015. Archives of Iranian Medicine, 2017, 20, S2-S6.	0.6	7
131	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Alborz, Iran. Archives of Iranian Medicine, 2017, 20, S7-S10.	0.6	0
132	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Ardebil, Iran. Archives of Iranian Medicine, 2017, 20, S11-S14.	0.6	2
133	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Bushehr, Iran. Archives of Iranian Medicine, 2017, 20, S15-S18.	0.6	0
134	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Chaharmahal and Bakhtiari, Iran. Archives of Iranian Medicine, 2017, 20, S19-S22.	0.6	2
135	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of East Azarbaijan, Iran. Archives of Iranian Medicine, 2017, 20, S23-S26.	0.6	1
136	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Fars, Iran. Archives of Iranian Medicine, 2017, 20, S27-S30.	0.6	1
137	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Gilan, Iran. Archives of Iranian Medicine, 2017, 20, S31-S34.	0.6	0
138	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Golestan, Iran. Archives of Iranian Medicine, 2017, 20, S35-S38.	0.6	0
139	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Hamadan, Iran. Archives of Iranian Medicine, 2017, 20, S39-S42.	0.6	1
140	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Hormozgan, Iran. Archives of Iranian Medicine, 2017, 20, S43-S46.	0.6	0
141	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Ilam, Iran. Archives of Iranian Medicine, 2017, 20, S47-S50.	0.6	0
142	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Isfahan, Iran. Archives of Iranian Medicine, 2017, 20, S51-S54.	0.6	0
143	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kerman, Iran. Archives of Iranian Medicine, 2017, 20, S55-S58.	0.6	0
144	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kermanshah, Iran. Archives of Iranian Medicine, 2017, 20, S59-S62.	0.6	1

#	ARTICLE	IF	CITATIONS
145	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Khouzestan, Iran. Archives of Iranian Medicine, 2017, 20, S63-S66.	0.6	1
146	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kohgiluyeh and Bouyerahmad, Iran. Archives of Iranian Medicine, 2017, 20, S67-S70.	0.6	0
147	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kordestan, Iran. Archives of Iranian Medicine, 2017, 20, S71-S74.	0.6	1
148	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Lorestan, Iran. Archives of Iranian Medicine, 2017, 20, S75-S78.	0.6	1
149	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Markazi, Iran. Archives of Iranian Medicine, 2017, 20, S79-S82.	0.6	2
150	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Mazandaran, Iran. Archives of Iranian Medicine, 2017, 20, S83-S86.	0.6	2
151	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of North Khorasan, Iran. Archives of Iranian Medicine, 2017, 20, S87-S90.	0.6	0
152	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Qazvin, Iran. Archives of Iranian Medicine, 2017, 20, S91-S94.	0.6	0
153	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Qom, Iran. Archives of Iranian Medicine, 2017, 20, S95-S98.	0.6	0
154	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Razavi Khorasan, Iran. Archives of Iranian Medicine, 2017, 20, S99-S102.	0.6	2
155	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Semnan, Iran. Archives of Iranian Medicine, 2017, 20, S103-S106.	0.6	2
156	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Sistan and Bluchestan, Iran. Archives of Iranian Medicine, 2017, 20, S107-S110.	0.6	1
157	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of South Khorasan, Iran. Archives of Iranian Medicine, 2017, 20, S111-S114.	0.6	0
158	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Tehran, Iran. Archives of Iranian Medicine, 2017, 20, S115-S118.	0.6	4
159	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of West Azarbaijan, Iran. Archives of Iranian Medicine, 2017, 20, S119-S122.	0.6	1
160	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Yazd, Iran. Archives of Iranian Medicine, 2017, 20, S123-S126.	0.6	1
161	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Zanzan, Iran. Archives of Iranian Medicine, 2017, 20, S127-S130.	0.6	0
162	Mental Health Survey of the Iranian Adult Population in 2015. Archives of Iranian Medicine, 2017, 20, 128-134.	0.6	64

#	ARTICLE	IF	CITATIONS
163	Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients. <i>International Clinical Psychopharmacology</i> , 2016, 31, 20-26.	1.7	60
164	The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. <i>Human Psychopharmacology</i> , 2016, 31, 103-112.	1.5	41
165	N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 214-219.	1.5	80
166	Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 332-341.	1.8	45
167	Next generation sequencing: implications in personalized medicine and pharmacogenomics. <i>Molecular BioSystems</i> , 2016, 12, 1818-1830.	2.9	82
168	Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 784-791.	1.3	37
169	Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: placebo-controlled, double-blind, randomized trial. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 517-526.	1.8	46
170	The role of phthalate esters in autism development: A systematic review. <i>Environmental Research</i> , 2016, 151, 493-504.	7.5	48
171	Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 513-519.	1.3	23
172	Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. <i>Journal of Affective Disorders</i> , 2016, 204, 1-8.	4.1	70
173	Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2016, 49, 162-169.	3.3	15
174	Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2016, 75, 24-30.	3.1	44
175	The Economic Aspects of Medical Biotechnology. <i>Avicenna Journal of Medical Biotechnology</i> , 2016, 8, 1.	0.3	0
176	Medical Biotechnology and Alzheimer's Disease: New Hopes. <i>Avicenna Journal of Medical Biotechnology</i> , 2016, 8, 1.	0.3	8
177	The Role of Lead Exposure on Attention-Deficit/ Hyperactivity Disorder in Children: A Systematic Review. <i>Iranian Journal of Psychiatry</i> , 2016, 11, 1-14.	0.7	44
178	The Importance of Clinical Trials in Drug Development. <i>Avicenna Journal of Medical Biotechnology</i> , 2016, 8, 151.	0.3	11
179	Health Research Governance: Introduction of a New Web-based Research Evaluation Model in Iran: One-decade Experience. <i>Iranian Journal of Public Health</i> , 2016, 45, 1309-1314.	0.5	2
180	Reliability and Validity of the Persian Version of Compulsive Eating Scale (CES) in Overweight or Obese Women and Its Relationship with Some Body Composition and Dietary Intake Variables. <i>Iranian Journal of Psychiatry</i> , 2016, 11, 250-256.	0.7	8

#	ARTICLE	IF	CITATIONS
181	Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2016, 5, 32-38.	0.2	10
182	Factors Associated with Anxiety in Premature Coronary Artery Disease Patients: THC-PAC Study. <i>Acta Medica Iranica</i> , 2016, 54, 261-9.	0.8	2
183	The Role of Medical Research Centers in Health Research System Promotion in I.R. of Iran: 2001-2014. <i>Archives of Iranian Medicine</i> , 2016, 20, 686-690.	0.6	4
184	Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial. <i>Pharmacopsychiatry</i> , 2015, 48, 268-273.	3.3	20
185	Celecoxib adjunctive therapy for acute bipolarÂmania: a randomized, double-blind, placebo-controlled trial. <i>Bipolar Disorders</i> , 2015, 17, 606-614.	1.9	78
186	Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 441-446.	1.5	24
187	Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2015, 29, 575-581.	4.0	60
188	Lipoid proteinosis: phenotypic heterogeneity in Iranian families with c.507delT mutation in <i>ECM</i> . <i>Experimental Dermatology</i> , 2015, 24, 220-222.	2.9	20
189	PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. <i>Depression and Anxiety</i> , 2015, 32, 167-173.	4.1	94
190	A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. <i>Psychiatry Research</i> , 2015, 229, 181-187.	3.3	53
191	Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2015, 49, 953-961.	1.9	36
192	Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2015, 23, 2.	2.0	36
193	Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. <i>Journal of Affective Disorders</i> , 2015, 183, 149-155.	4.1	50
194	N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism. <i>Clinical Neuropharmacology</i> , 2015, 38, 11-17.	0.7	86
195	Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial. <i>Pharmacopsychiatry</i> , 2015, 48, 136-140.	3.3	51
196	Are Supplementation of Omega-3 and Ascorbic Acid Effective in Reducing Oxidative Stress and Depression among Depressed Shift Workers?. <i>International Journal for Vitamin and Nutrition Research</i> , 2015, 85, 299-310.	1.5	14
197	Autistic disorders and medical biotechnology. <i>Avicenna Journal of Medical Biotechnology</i> , 2015, 7, 1.	0.3	6
198	Evidence Based Medicine and Medical Biotechnology. <i>Avicenna Journal of Medical Biotechnology</i> , 2015, 7, 133.	0.3	0

#	ARTICLE	IF	CITATIONS
199	Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2015, 10, 106-14.	0.7	9
200	A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. <i>Acta Medica Iranica</i> , 2015, 53, 337-45.	0.8	19
201	Mental health study process into prevalence of mental disorders in Iran. <i>Archives of Iranian Medicine</i> , 2015, 18, 74-5.	0.6	7
202	Establishment of the National Network of WHO Collaborating Centres in Iran to Contribute to the National Public Health Needs. <i>Archives of Iranian Medicine</i> , 2015, 18, 558-9.	0.6	0
203	Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 677-685.	4.0	62
204	Comparing Effects of Ketamine and Thiopental Administration During Electroconvulsive Therapy in Patients With Major Depressive Disorder. <i>Journal of ECT</i> , 2014, 30, 15-21.	0.6	85
205	Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 344-350.	1.7	42
206	Sudden hearing loss subsequent to diarrhea: what is the missing link?. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2014, 22, 15.	2.0	8
207	A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 533-542.	3.1	34
208	Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. <i>Psychiatry Research</i> , 2014, 215, 540-546.	3.3	87
209	A randomized, double-blind, clinical trial comparing the efficacy and safety of <i>Crocus sativus</i> L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. <i>Journal of Affective Disorders</i> , 2014, 155, 216-222.	4.1	111
210	Comparing the efficacy and safety of <i>Crocus sativus</i> L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. <i>Human Psychopharmacology</i> , 2014, 29, 351-359.	1.5	114
211	l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial. <i>Journal of Psychiatric Research</i> , 2014, 59, 125-131.	3.1	30
212	Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2014, 22, 55.	2.0	37
213	Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial. <i>Psychiatry Research</i> , 2014, 219, 431-435.	3.3	33
214	Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 846-855.	0.7	17
215	Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: A randomized double blind placebo controlled clinical trial. <i>Journal of Affective Disorders</i> , 2014, 166, 201-205.	4.1	23
216	Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. <i>Swiss Medical Weekly</i> , 2014, 144, w13880.	1.6	16

#	ARTICLE	IF	CITATIONS
217	Avicenna and evidence based medicine. <i>Avicenna Journal of Medical Biotechnology</i> , 2014, 6, 1-2.	0.3	25
218	Personalized medicine: a tailor made medicine. <i>Avicenna Journal of Medical Biotechnology</i> , 2014, 6, 191.	0.3	10
219	Personality Patterns in Narcotics Anonymous Members versus Individuals with Addiction Receiving Methadone Maintenance Therapy. <i>Iranian Journal of Psychiatry</i> , 2014, 9, 158-62.	0.7	0
220	Oxidative Stress and Depression among Male Shift Workers in Shahid Tondgouyan Refinery. <i>Iranian Journal of Psychiatry</i> , 2014, 9, 76-82.	0.7	7
221	Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. <i>Acta Medica Iranica</i> , 2014, 52, 675-80.	0.8	15
222	Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. <i>Acta Medica Iranica</i> , 2014, 52, 734-9.	0.8	25
223	A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. <i>Psychopharmacology</i> , 2013, 228, 595-602.	3.1	36
224	Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2013, 225, 51-59.	3.1	109
225	Cyproheptadine for Prevention of Neuropsychiatric Adverse Effects of Efavirenz: A Randomized Clinical Trial. <i>AIDS Patient Care and STDs</i> , 2013, 27, 146-154.	2.5	13
226	Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial. <i>Paediatric Drugs</i> , 2013, 15, 505-514.	3.1	47
227	Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia. <i>CNS Drugs</i> , 2013, 27, 57-65.	5.9	99
228	Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 650-656.	1.9	47
229	Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 175-180.	3.1	123
230	Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. <i>Psychoneuroendocrinology</i> , 2013, 38, 767-776.	2.7	101
231	Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. <i>Human Psychopharmacology</i> , 2013, 28, 54-60.	1.5	95
232	Nutrients for Prevention and Treatment of Mental Health Disorders. <i>Psychiatric Clinics of North America</i> , 2013, 36, 25-36.	1.3	21
233	Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 472-478.	3.1	25
234	Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 783-789.	2.1	98

#	ARTICLE	IF	CITATIONS
235	Saffron, Passionflower, Valerian and Sage for Mental Health. <i>Psychiatric Clinics of North America</i> , 2013, 36, 85-91.	1.3	22
236	N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia. <i>Clinical Neuropharmacology</i> , 2013, 36, 185-192.	0.7	121
237	Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism. <i>Clinical Neuropharmacology</i> , 2013, 36, 179-184.	0.7	44
238	Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 336-342.	1.4	48
239	Total Antioxidant Capacity and Malondialdehyde in Depressive Rotational Shift Workers. <i>Journal of Environmental and Public Health</i> , 2013, 2013, 1-5.	0.9	9
240	Effect of omega-3 and ascorbic acid on inflammation markers in depressed shift workers in Shahid Tondgoyan Oil Refinery, Iran: a randomized double-blind placebo-controlled study. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2013, 53, 36-40.	1.4	22
241	Cardiovascular considerations in antidepressant therapy: an evidence-based review. <i>The Journal of Tehran Heart Center</i> , 2013, 8, 169-76.	0.3	21
242	Glutathione-Related Factors and Oxidative Stress in Autism, A Review. <i>Current Medicinal Chemistry</i> , 2012, 19, 4000-4005.	2.4	111
243	Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2012, 37, 2093-2100.	5.4	126
244	Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. <i>Psychopharmacology</i> , 2012, 223, 381-388.	3.1	94
245	A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders. <i>Child Psychiatry and Human Development</i> , 2012, 43, 674-682.	1.9	34
246	Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. <i>Journal of Affective Disorders</i> , 2012, 141, 308-314.	4.1	280
247	Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2012, 20, 43.	2.0	10
248	Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder. <i>CNS Drugs</i> , 2012, 26, 883-892.	5.9	58
249	Allopurinol and related drugs for schizophrenia. <i>The Cochrane Library</i> , 2012, , .	2.8	1
250	A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. <i>Psychopharmacology</i> , 2012, 220, 591-598.	3.1	20
251	Bupropion versus methylphenidate in the treatment of children with attention deficit/hyperactivity disorder: randomized double-blind study. <i>Human Psychopharmacology</i> , 2012, 27, 411-418.	1.5	33
252	Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1428-1433.	2.2	81

#	ARTICLE	IF	CITATIONS
253	Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry, 2012, 7, 87-92.	0.7	43
254	Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co-administration: Through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry, 2012, 7, 114-9.	0.7	16
255	Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study. Acta Medica Iranica, 2012, 50, 723-8.	0.8	10
256	Celecoxib for schizophrenia. The Cochrane Library, 2011, , .	2.8	3
257	Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of Affective Disorders, 2011, 129, 327-331.	4.1	80
258	Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial. Child Psychiatry and Human Development, 2011, 42, 367-375.	1.9	26
259	Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. Quality of Life Research, 2011, 20, 31-36.	3.1	62
260	Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology, 2011, 213, 809-815.	3.1	40
261	Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depression and Anxiety, 2011, 28, 297-302.	4.1	47
262	Author's response to Yang R <i>et al</i> .: Several concerns arise when the results are interpreted. Human Psychopharmacology, 2011, 26, 88-88.	1.5	0
263	Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Human Psychopharmacology, 2011, 26, 120-124.	1.5	12
264	Cardiovascular effects of saffron: an evidence-based review. Journal of Tehran University Heart Center, 2011, 6, 59-61.	0.2	17
265	Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy. Acta Medica Iranica, 2011, 49, 487-98.	0.8	13
266	A Double-Blind, Randomized, and Placebo-Controlled Trial of Bupirone Added to Risperidone in Patients With Chronic Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 678-682.	1.4	25
267	A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology, 2010, 207, 637-643.	3.1	202
268	Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Human Psychopharmacology, 2010, 25, 530-535.	1.5	27
269	Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Human Psychopharmacology, 2010, 25, 560-565.	1.5	25
270	Published research on attention deficit hyperactivity disorder : a comparative analysis of <sc>medline</sc> and an Iranian bibliographic database. Health Information and Libraries Journal, 2010, 27, 155-157.	2.5	1

#	ARTICLE	IF	CITATIONS
271	ORIGINAL ARTICLE: Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 581-588.	1.5	190
272	The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. <i>Schizophrenia Research</i> , 2010, 116, 101-106.	2.0	65
273	Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 32-36.	4.8	80
274	Ginkgo biloba for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 76-80.	4.8	66
275	Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1269-1272.	4.8	99
276	Efficacy and Safety of Oral Combination of Yohimbine and L-arginine (SX) for the Treatment of Erectile Dysfunction: a multicenter, randomized, double blind, placebo-controlled clinical trial. <i>Iranian Journal of Psychiatry</i> , 2010, 5, 1-3.	0.7	14
277	Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. <i>Depression and Anxiety</i> , 2009, 26, 607-611.	4.1	328
278	Major Depressive Disorder in Children and Adolescents After Renal Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1627-1629.	0.6	7
279	A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. <i>Psychiatry Research</i> , 2009, 168, 234-237.	3.3	69
280	Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. <i>Schizophrenia Research</i> , 2009, 107, 206-212.	2.0	93
281	Comparing the Effects of High-Dose Vitamin E With Those of Placebo on Insulin Resistance in Patients With Schizophrenia Treated With Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 182-183.	1.4	10
282	The meeting of psychiatry and humanities: an overview. <i>Journal of Medical Ethics and History of Medicine</i> , 2009, 2, 5.	0.6	1
283	A Double-blind Placebo Controlled Trial of Piracetam Added to Risperidone in Patients with Autistic Disorder. <i>Child Psychiatry and Human Development</i> , 2008, 39, 237-245.	1.9	51
284	Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. <i>Human Psychopharmacology</i> , 2008, 23, 79-86.	1.5	31
285	<i>Crocus sativus</i> L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 515-519.	2.3	150
286	Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 145-149.	4.8	64
287	A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 726-732.	4.8	25
288	A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1810-1815.	4.8	40

#	ARTICLE	IF	CITATIONS
289	Effect of ritanserin, a 5HT _{2A/2C} antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1879-1883.	4.8	64
290	Autism Spectrum Disorders: Etiology and Pharmacotherapy. <i>Current Drug Therapy</i> , 2007, 2, 97-103.	0.3	13
291	Combination of citalopram and nortriptyline in the treatment of severe major depression: a double-blind, placebo-controlled trial. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 187-192.	0.2	5
292	Comparison of petal of <i>Crocus sativus</i> L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 439-442.	4.8	175
293	Antidepressant-like effect of magnetic resonance imaging-based stimulation in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 503-509.	4.8	12
294	Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. <i>Schizophrenia Research</i> , 2007, 90, 179-185.	2.0	275
295	Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 195-201.	2.8	43
296	Herbal Medicines in the Treatment of Psychiatric and Neurological Disorders. , 2007, , 119-138.		13
297	Allopurinol as Adjunctive Therapy in Intractable Epilepsy: A Double-blind and Placebo-controlled Trial. <i>Archives of Medical Research</i> , 2007, 38, 313-316.	3.3	40
298	Herbal medicine in the treatment of Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006, 21, 113-118.	1.9	109
299	Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. <i>Schizophrenia Research</i> , 2006, 84, 405-410.	2.0	142
300	Pharmacotherapy of Schizophrenia: The Past, Present and Future. <i>Current Drug Therapy</i> , 2006, 1, 1-7.	0.3	18
301	Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. <i>Bipolar Disorders</i> , 2006, 8, 485-489.	1.9	75
302	<i>Crocus sativus</i> L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. <i>Phytomedicine</i> , 2006, 13, 607-611.	5.3	184
303	Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. <i>Archives of Iranian Medicine</i> , 2006, 9, 374-80.	0.6	10
304	Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 745-751.	0.2	4
305	Topiramate prevents ecstasy consumption: a case report. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 601-602.	1.9	11
306	Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 133-138.	1.5	18

#	ARTICLE	IF	CITATIONS
307	Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. <i>Phytotherapy Research</i> , 2005, 19, 148-151.	5.8	231
308	Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 399-406.	0.2	2
309	<i>Passiflora incarnata</i> in the treatment of attention-deficit hyperactivity disorder in children and adolescents. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 609-614.	0.2	22
310	Hydro-alcoholic extract of <i>Crocus sativus</i> L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. <i>Journal of Ethnopharmacology</i> , 2005, 97, 281-284.	4.1	230
311	Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabetic outpatients. <i>Journal of Ethnopharmacology</i> , 2005, 102, 202-207.	4.1	147
312	Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 253-259.	4.8	83
313	<i>Passiflora incarnata</i> in the treatment of attention-deficit hyperactivity disorder in children and adolescents. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 609-614.	0.2	6
314	Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 399-406.	0.2	0
315	Allopurinol as adjunctive treatment for acute mania in hospitalized bipolar patients. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 739-744.	0.2	0
316	Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 745-751.	0.2	1
317	Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 139-144.	1.5	20
318	Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 145-150.	1.5	40
319	Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience. <i>BMC Neurology</i> , 2004, 4, 12.	1.8	34
320	Prevalence of obsessive-compulsive disorder in Iran. <i>BMC Psychiatry</i> , 2004, 4, 2.	2.6	81
321	Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]. <i>BMC Psychiatry</i> , 2004, 4, 9.	2.6	158
322	Comparison of <i>Crocus sativus</i> L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816]. <i>BMC Complementary and Alternative Medicine</i> , 2004, 4, 12.	3.7	217
323	Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. <i>BMC Psychiatry</i> , 2003, 3, 7.	2.6	16
324	Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 379-384.	1.5	14

#	ARTICLE	IF	CITATIONS
325	Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 53-59.	1.5	248
326	Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 123-127.	4.8	103
327	Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 841-845.	4.8	57
328	Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1007-1012.	4.8	124
329	Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 863-866.	1.9	196
330	Hydroxyzine may be safe and effective in generalised anxiety disorder. <i>Evidence-Based Mental Health</i> , 2003, 6, 91-91.	4.5	1
331	Cyproheptadine in treatment of autism. <i>European Psychiatry</i> , 2002, 17, 230-231.	0.2	5
332	Potentiation of muscimol-induced long-term depression by benzodiazepines but not zolpidem. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 1161-1166.	4.8	5
333	Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia*. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 453-459.	1.5	13
334	Alzheimer's disease: pathophysiology and pharmacotherapy. <i>IDrugs: the Investigational Drugs Journal</i> , 2002, 5, 1062-9.	0.7	6
335	Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 369-373.	1.5	74
336	Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 363-367.	1.5	190
337	Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 67-71.	1.5	30
338	Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 131-137.	1.5	96
339	Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 347-353.	1.5	70
340	Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 49-52.	1.5	28
341	Hippocampal synaptic plasticity and cognition. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 241-248.	1.5	57
342	Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 369-374.	1.5	65

#	ARTICLE	IF	CITATIONS
343	Is it time to have another look at lithium maintenance therapy in bipolar disorder?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 1011-1017.	4.8	2
344	Prevention of muscimol-induced long-term depression by brain-derived neurotrophic factor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 1215-1226.	4.8	3
345	POTENTIATION OF MUSCIMOL-INDUCED LONG-TERM DEPRESSION BY BENZODIAZEPINES AND PREVENTION OR REVERSAL BY PREGNENOLONE SULFATE. Pharmacological Research, 1998, 38, 441-448.	7.1	9
346	Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 155-159.	1.5	6
347	Muscimol-induced long-term depression in the hippocampus: Lack of dependence on extracellular calcium. Neuroscience, 1996, 71, 581-588.	2.3	6
348	Maintenance of muscimol-induced long-term depression by neurosteroids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 277-289.	4.8	3
349	Glutamate-independent long-term depression in rat hippocampus by activation of GABAA receptors. Life Sciences, 1996, 58, 1023-1030.	4.3	8
350	Potentiation by neurosteroids of muscimol/adenosine interactions in rat hippocampus. Brain Research, 1995, 677, 311-318.	2.2	5
351	Interaction between adenosine and GABAA receptors on hippocampal neurones. Brain Research, 1994, 665, 229-236.	2.2	28
352	Autism Spectrum Disorders in Iran. , 0, , .		4
353	Melatonin Effects in Women With Comorbidities of Overweight, Depression, and Sleep Disturbance: A Randomized Placebo Controlled Clinical Trial. Sleep Medicine Research, 0, , .	0.6	0